114 related articles for article (PubMed ID: 32530559)
1. Hyaluronic acid for the treatment of airway diseases in children: Little evidence for few indications.
Di Cicco M; Peroni D; Sepich M; Tozzi MG; Comberiati P; Cutrera R
Pediatr Pulmonol; 2020 Aug; 55(8):2156-2169. PubMed ID: 32530559
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid and upper airway inflammation in pediatric population: A systematic review.
Casale M; Vella P; Moffa A; Oliveto G; Sabatino L; Grimaldi V; Ferrara P; Salvinelli F
Int J Pediatr Otorhinolaryngol; 2016 Jun; 85():22-6. PubMed ID: 27240491
[TBL] [Abstract][Full Text] [Related]
3. Use of Hyaluronic Acid (HA) in Chronic Airway Diseases.
Máiz Carro L; Martínez-García MA
Cells; 2020 Sep; 9(10):. PubMed ID: 33003557
[TBL] [Abstract][Full Text] [Related]
4. Pilot Randomized Controlled Trial Evaluating the Effect of Hypertonic Saline With and Without Hyaluronic Acid in Reducing Inflammation in Cystic Fibrosis.
Brivio A; Conese M; Gambazza S; Biffi A; Tirelli AS; Russo M; Foà M; Colombo C
J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):482-489. PubMed ID: 27149365
[TBL] [Abstract][Full Text] [Related]
5. Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease.
Lamas A; Marshburn J; Stober VP; Donaldson SH; Garantziotis S
Respir Res; 2016 Oct; 17(1):123. PubMed ID: 27716205
[TBL] [Abstract][Full Text] [Related]
6. The role of hyaluronan in the pathobiology and treatment of respiratory disease.
Garantziotis S; Brezina M; Castelnuovo P; Drago L
Am J Physiol Lung Cell Mol Physiol; 2016 May; 310(9):L785-95. PubMed ID: 26747781
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of topical hyaluronan in rhinosinusitis: a systematic review.
Casale M; Vella P; Moffa A; Grimaldi V; Sabatino L; Rinaldi V; Lopez MA; Baptista P; Salvinelli F
J Biol Regul Homeost Agents; 2017 Dec; 31(4 Suppl 2):71-80. PubMed ID: 29202565
[TBL] [Abstract][Full Text] [Related]
8. Nebulized hyaluronan ameliorates lung inflammation in cystic fibrosis mice.
Gavina M; Luciani A; Villella VR; Esposito S; Ferrari E; Bressani I; Casale A; Bruscia EM; Maiuri L; Raia V
Pediatr Pulmonol; 2013 Aug; 48(8):761-71. PubMed ID: 22825912
[TBL] [Abstract][Full Text] [Related]
9. Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study.
Galdi F; Pedone C; McGee CA; George M; Rice AB; Hussain SS; Vijaykumar K; Boitet ER; Tearney GJ; McGrath JA; Brown AR; Rowe SM; Incalzi RA; Garantziotis S
Respir Res; 2021 Feb; 22(1):30. PubMed ID: 33517896
[TBL] [Abstract][Full Text] [Related]
10. Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients.
Máiz L; Girón RM; Prats E; Clemente MG; Polverino E; Caño S; Cordovilla R; Dorca J; Peñalver C; Baranda F; Martínez-García MA
Ther Adv Respir Dis; 2018; 12():1753466618787385. PubMed ID: 30014774
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic and clinical benefits of hyaluronic acid in children with chronic adenoiditis and middle ear disease.
Torretta S; Marchisio P; Rinaldi V; Carioli D; Nazzari E; Pignataro L
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1423-1429. PubMed ID: 27695944
[TBL] [Abstract][Full Text] [Related]
12. Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial.
Herrero-Cortina B; Alcaraz V; Vilaró J; Torres A; Polverino E
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):281-289. PubMed ID: 29878856
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial.
Ros M; Casciaro R; Lucca F; Troiani P; Salonini E; Favilli F; Quattrucci S; Sher D; Assael BM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):133-7. PubMed ID: 23745525
[TBL] [Abstract][Full Text] [Related]
14. High molecular weight hyaluronan attenuates fine particulate matter-induced acute lung injury through inhibition of ROS-ASK1-p38/JNK-mediated epithelial apoptosis.
Xu C; Shi Q; Zhang L; Zhao H
Environ Toxicol Pharmacol; 2018 Apr; 59():190-198. PubMed ID: 29625389
[TBL] [Abstract][Full Text] [Related]
15. The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.
Dhand R
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):121-138. PubMed ID: 29077527
[TBL] [Abstract][Full Text] [Related]
16. Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials.
Sucharew H; Goss CH; Millard SP; Ramsey BW;
Contemp Clin Trials; 2006 Dec; 27(6):561-70. PubMed ID: 16875884
[TBL] [Abstract][Full Text] [Related]
17. Activity of budesonide on nasal neutrophilic inflammation and obstruction in children with recurrent upper airway infections. A preliminary investigation.
Bellodi S; Tosca MA; Pulvirenti G; Petecchia L; Serpero L; Silvestri M; Sabatini F; Battistini E; Rossi GA
Int J Pediatr Otorhinolaryngol; 2006 Mar; 70(3):445-52. PubMed ID: 16140398
[TBL] [Abstract][Full Text] [Related]
18. Oral steroids for long-term use in cystic fibrosis.
Cheng K; Ashby D; Smyth RL
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD000407. PubMed ID: 26649765
[TBL] [Abstract][Full Text] [Related]
19. Nebulised hypertonic saline for cystic fibrosis.
Wark PA; McDonald V
Cochrane Database Syst Rev; 2000; (2):CD001506. PubMed ID: 10796798
[TBL] [Abstract][Full Text] [Related]
20. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.
Tay GT; Reid DW; Bell SC
Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
